ArticleSpine surgery and related research2026
Efficacy of Corticosteroid Addition to Selective Nerve Root Block for Lumbar Radiculopathy: A Multicenter Prospective Cohort Study.
Article in Spine surgery and related research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The addition of corticosteroids to selective nerve root block (SNRB) is widely practiced for lumbar radiculopathy, yet robust evidence regarding its efficacy for functional outcomes remains limited. We evaluated whether adding corticosteroids to local anesthetic in SNRB relieves functional disability and improves quality of life in patients with lumbar radiculopathy. Methods: This multicenter, prospective cohort study enrolled 78 patients with single-level lumbar radiculopathy. Patients received fluoroscopy-guided SNRB with either corticosteroids (dexamethasone, betamethasone) plus 1% lidocaine (n=64) or lidocaine alone (n=14). The primary outcome was the Oswestry Disability Index (ODI) at 90 and 180 days. Secondary outcomes included visual analog scale (VAS) scores for leg pain, Japanese Orthopaedic Association Back Pain Evaluation Questionnaire (JOABPEQ), and minimal clinically important difference (MCID) achievement rates. Linear mixed-effects models were used for analysis. Results: The steroid group indicated significantly greater ODI improvement at 90 days (27.9 vs 47.1; mean difference, 19.2 points [95% confidence interval (CI), 6.8-31.6]; p=0.002) and 180 days (29.0 vs 44.1; mean difference, 15.1 points [95% CI, 2.3-27.9]; p=0.022), with large effect sizes (Cohen d>0.8). Significant improvements favoring corticosteroids were observed for VAS scores at 90 days (3.5 vs 5.7; p=0.018) and 180 days (3.7 vs 5.9; p=0.023) and multiple JOABPEQ domains. MCID achievement was significantly higher in the steroid group at 90 days (75.0% vs 33.3%; p=0.043); the number needed to treat was 2.4. Adverse event rates were similar in the groups, and no serious adverse events occurred. Benefits plateaued between 90 and 180 days. Conclusions: Adding non-particulate corticosteroids to SNRB significantly relieved functional disability and pain and improved quality of life in patients with lumbar radiculopathy, with the most pronounced group differences occurring at 90 days and sustained through 180 days. Clinically, the 90-day timepoint is optimal for evaluating treatment success and determining the need for alternative treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.